mRNA-1403

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

Acute GastroenteritisNorovirus Acute Gastroenteritis

Phase 1

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Active, not recruitingNCT05992935

ModernaTX, Inc.Norovirus Acute Gastroenteritis

Start: 2023-08-25End: 2026-09-22Updated: 2026-04-03

Phase 3

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

Active, not recruitingNCT06592794

ModernaTX, Inc.Acute Gastroenteritis, Norovirus Acute Gastroenteritis

Start: 2024-09-24End: 2027-02-15Updated: 2026-05-13

Related Papers

P-1505. Cellular and Humoral Immunogenicity of 1 or 2 injections of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults

Open Forum Infectious Diseases2026-01-01

575. Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial

Open Forum Infectious Diseases2025-01-293 citations